Keywords: patients, rad001, achieve, stable, pancreatic, net, tumors
77% of patients on RAD001 achieve stable pancreatic NET tumors
Article | 22 September 2008
Novartis' RAD001 (everolimus) alone and in combination with Sandostatin LAR Depot (octreotide acetate for injectable suspension) controls tumor growth in ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
